Moderna Says Its Vaccine Is 96% Effective in Teens The pharmaceutical company made the announcement while also revealing its financial results for the first quarter.

By Justin Chan

On Thursday, pharmaceutical company Moderna announced, alongside the release of its financial results, that its Covid-19 vaccine is 96% effective in teens between the ages of 12- and 17-years-old.

An early analysis of the vaccine in adolescents in the aforementioned age range shows that the shot was "generally well tolerated with no serious safety concerns identified to date," the company said.

Related: The Moderna Pullback Is Worth a Shot

With its Covid-19 vaccine as one of three to receive approval from the FDA, Moderna added that it would increase its base plan for this year to 800 million doses in an effort to reach 1 billion doses by the end of 2021. It currently has an agreement with the U.S. to manufacture 300 million doses (enough to fully vaccinate 100 million Americans), according to CNBC. The company said it is now "actively engaged" in discussions and agreements for next year with other countries it has been supplying.

"In the first quarter, the Moderna team delivered on its supply commitments to many governments and helped protect more than 100 million people," CEO Stéphane Bancel said in a statement. "This accomplishment translated into our first profitable quarter in the company's history, after 10 years of scientific innovation and several billion dollars invested to make our mRNA platform [a protein-making template] a reality."

In the three months ending on March 31, Moderna's total revenue reached $1.9 billion as a result of commercial sales of the vaccine, the company's financial results reveal. The figure represented a huge leap from the $8 million Moderna earned in the same period last year.

The company also said its product sales were $1.7 billion in the first three months and that its cost of sales hovered around $193 million. Additionally, Moderna's net income was $1.2 billion compared to a net loss of $124 million in the same period in 2020.

On Wednesday, the company announced that a booster shot given to previously vaccinated adults showed a positive response against the B.1.351 and P.1 variants found respectively in South Africa and Brazil.

Justin Chan

Entrepreneur Staff

News Writer

Justin Chan is a news writer at Previously, he was a trending news editor at Verizon Media, where he covered entrepreneurship, lifestyle, pop culture, and tech. He was also an assistant web editor at Architectural Record, where he wrote on architecture, travel, and design. Chan has additionally written for Forbes, Reader's Digest, Time Out New YorkHuffPost, Complex, and Mic. He is a 2013 graduate of Columbia Journalism School, where he studied magazine journalism. Follow him on Twitter at @jchan1109.

Editor's Pick

Related Topics


Don't Miss This Sam's Club Membership Deal for Just $20

Your last chance for a great deal on a membership that helps you save money all year long.


This $126 Apple- and Android-Compatible Display Can Help You Drive Safer

Adding this display will elevate your older model car for an affordable price.

Business Ideas

55 Small Business Ideas to Start in 2023

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2023.

Data & Recovery

This Cyber Week Exclusive Gets You 1TB of Cloud Storage for $120

If you're looking for a reliable cloud storage solution, look no further than Koofr.

Growing a Business

Serial Entrepreneur Turned VC Reveals 4 Numbers You Need to Know to Scale Your Company

If you're looking to attract investment or simply seeking to scale your business, there are four key numbers you should use as your guiding light.

Thought Leaders

3 New Ways to Develop Laser-Like Focus

To boost focus in the face of distractions, you need a new approach to success.